Alpha Cognition Inc. (ACOG)
NASDAQ: ACOG · Real-Time Price · USD
5.08
-0.26 (-4.87%)
At close: Mar 27, 2026, 4:00 PM EDT
5.09
+0.01 (0.20%)
After-hours: Mar 27, 2026, 4:10 PM EDT
Alpha Cognition Revenue
In the year 2025, Alpha Cognition had annual revenue of $10.22M. Alpha Cognition had revenue of $2.79M in the quarter ending December 31, 2025.
Revenue (ttm)
$10.22M
Revenue Growth
n/a
P/S Ratio
10.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
110.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.22M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Black Diamond Therapeutics | 70.00M |
| Q32 Bio | 53.74M |
| Sangamo Therapeutics | 32.88M |
| Equillium | 4.39M |
| Rani Therapeutics Holdings | 1.63M |
| Cardiff Oncology | 593.00K |
| Inovio Pharmaceuticals | 65.34K |
ACOG News
- 2 days ago - Alpha Cognition Inc. (ACOG) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update - Business Wire
- 16 days ago - Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 - Business Wire
- 19 days ago - Alpha Cognition to Present New Clinical on ZUNVEYL® (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences - Business Wire
- 4 weeks ago - Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study - Business Wire
- 5 weeks ago - Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL ® Dosing Regimens - Business Wire
- 2 months ago - Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution - Business Wire
- 4 months ago - Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript - Seeking Alpha